Document:

exv10w1

Exhibit 10.1

RED LION HOTELS CORPORATION

SUMMARY OF TERMS OF EMPLOYMENT AGREEMENT

OF

JON E. ELIASSEN

	 	 	 

	Title:

	 	Interim President and Chief Executive Officer
	 
	 	 
	Term:

	 	At will
	 
	 	 
	Salary:

	 	$360,000 per year. Mr. Eliassen is separately compensated for service as a director on the same basis and under the
same terms and conditions as the Company’s non-employee directors.
	 
	 	 
	Bonus:

	 	Mr. Eliassen is not eligible to participate in the Company’s Executive Officers Variable Pay Plan.
	 
	 	 
	Benefits:

	 	Mr. Eliassen is eligible to participate in all benefit programs generally available to employees of the Company,
subject to applicable waiting periods and other conditions to participation.Exhibit 10.1

Exhibit 10.1

AMENDMENT TO

CREDIT AGREEMENT

THIS AMENDMENT TO CREDIT AGREEMENT (this “Amendment”) is being executed and delivered as of April 26, 2010
by and among CALENCE, LLC, a Delaware limited liability company (“Calence”), INSIGHT DIRECT USA, INC., an
Illinois corporation (“Insight Direct”), INSIGHT PUBLIC SECTOR, INC., an Illinois corporation (“Insight
Public”, and collectively with Calence and Insight Direct, the “Resellers” and each, a “Reseller”),
and certain of the Lenders party to the Credit Agreement described below. All capitalized terms used herein without
definition shall have the same meanings as set forth in the Credit Agreement.

W I T N E S S E T H:

WHEREAS, the Resellers, the Lenders, and the Administrative Agents are parties to that certain Credit Agreement,
dated as of September 17, 2008 (as amended, restated, amended and restated, supplemented or otherwise modified from
time to time, the “Credit Agreement”);

WHEREAS, Section 3.3 of the Credit Agreement imposes a Commitment Block upon Castle Pines Capital LLC
(“CPC”) that causes that portion, if any, of the Commitment of CPC in excess of $30,000,000 to be ineffective
with respect to determining CPC’s Pro-Rata Share;

WHEREAS, the Resellers, the Required Lenders and the Administrative Agents desire to remove the Commitment Block;
and

WHEREAS, the Resellers, the Required Lenders and the Administrative Agents have agreed to amend the Credit
Agreement on the terms and conditions set forth herein.

NOW, THEREFORE, in consideration of the foregoing premises, the terms and conditions stated herein and other
valuable consideration, the receipt and sufficiency of which are hereby acknowledged by the parties hereto, such
parties hereby agree as follows:

1. Amendment. Subject to the satisfaction of the condition precedent set forth in Section 2
below, the Resellers, the Required Lenders and the Administrative Agents party hereto hereby agree:

a. that the provisions of Section 3.3 of the Credit Agreement shall be deleted in their entirety and in their
place shall have been substituted the following:

“3.3 Reserved.”; and

b. upon the Effective Date, to replace Exhibit A of the Credit Agreement with the attached
Exhibit A.

2. Condition of Effectiveness. This Amendment shall be deemed to have become effective as of the date
hereof (the “Effective Date”), but such effectiveness shall be subject to the conditions precedent that the
Administrative Agents shall have received executed counterparts of this Amendment duly executed and delivered by each Reseller and the Required Lenders.

 

1

 

3. Representation and Warranties. Each Reseller hereby represents and warrants that (i) after giving
effect to this Amendment, all of the representations and warranties of such Reseller set forth in the Credit Agreement
are true and correct in all material respects on and as of the date hereof (except to the extent such representations
or warranties specifically relate to any earlier date, in which case such representations and warranties shall have
been true and correct in all material respects as of such earlier date) and (ii) after giving effect to this Amendment,
no Default has occurred or is continuing.

4. Effect on the Credit Agreement.

Upon the effectiveness of this Amendment, on and after the date hereof, each reference in the Credit Agreement to
“this Agreement,” “hereunder,” “hereof,” “herein” or words of like import shall mean and be a reference to the Credit
Agreement, as modified hereby.

5. GOVERNING LAW. THIS AMENDMENT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE
STATE OF NEW YORK.

6. Headings. Section headings in this Amendment are included herein for convenience of reference only and
shall not constitute a part of this Amendment for any other purpose.

7. Counterparts. This Amendment may be executed by one or more of the parties on any number of separate
counterparts and all of said counterparts taken together shall be deemed to constitute one and the same instrument. A
facsimile copy of any signature hereto shall have the same effect as the original thereof.

[Signature Pages Follow]

2

 

2

 

EXHIBIT A

LENDERS’ FACILITIES AND PRO-RATA SHARES

	 	 	 	 	 	 	 	 	 
	 	 	FLOORPLAN LOAN	 	PRO-RATA
	LENDER	 	FACILITY	 	SHARES
	CPC
	 	$	40,000,000	 	 	 	40	%
	 
	 	 	 	 	 	 	 	 
	Compass Bank
	 	$	10,000,000	 	 	 	10	%
	 
	 	 	 	 	 	 	 	 
	DeLage Landen Financial Services
	 	$	25,000,000	 	 	 	25	%
	 
	 	 	 	 	 	 	 	 
	IBM Credit LLC
	 	$	25,000,000	 	 	 	25	%
	 
	 	 	 	 	 	 	 	 
	Aggregates
	 	$	100,000,000	 	 	 	100	%
	 
	 	 	 	 	 	 	 	 

3

 

3

 

IN WITNESS WHEREOF, this Amendment has been duly executed as of the day and year first above written.

CALENCE, LLC, as a Reseller

By: Insight Enterprises, Inc., its Manager

By: /s/ Helen K. Johnson

Name: Helen K. Johnson

Title: Treasurer

INSIGHT DIRECT USA, INC., as a Reseller

By: /s/ Helen K. Johnson

Name: Helen K. Johnson

Title: Treasurer

INSIGHT PUBLIC SECTOR, INC., as a Reseller

By: /s/ Helen K. Johnson

Name: Helen K. Johnson

Title: Treasurer

Signature Page to

Amendment to Credit Agreement

 

4

 

CASTLE PINES CAPITAL LLC,

as Administrative Agent and Lender

By: /s/ John M. Schmidt

Name: John M. Schmidt

Title: Managing Partner

WELLS FARGO CAPITAL FINANCE LLC, formerly known as Wells Fargo Foothill, LLC,

as Administrative Agent and Collateral Agent

By: /s/ John Hanley

Name: John Hanley

Title: EVP

Signature Page to

Amendment to Credit Agreement

 

5

 

DE LAGE LANDEN FINANCIAL SERVICES, INC., as a Lender

By: /s/ Michael L. Jordan

Name: Michael L. Jordan

Title: Credit Process Manager

Signature Page to

Amendment to Credit Agreement

 

6

 

IBM CREDIT LLC, as a Lender

By: /s/ Steven A. Flanagan

Name: Steven A. Flanagan

Title: Global Credit Officer

Signature Page to

Amendment to Credit Agreement

 

7exv10w5

Exhibit 10.5

SETTLEMENT AGREEMENT

     This Settlement Agreement (“Agreement”) is entered into by and among the United States of
America, acting through the United States Department of Justice on behalf of the Office of
Inspector General (“OIG-HHS”) of the Department of Health and Human Services (“HHS”), the TRICARE
Management Activity (“TMA”), and the United States Office of Personnel Management (“OPM”)
(collectively, “the United States”); Alpharma Inc.; Alpharma Pharmaceuticals LLC; and Relator Debra
Parks (“Relator”), and solely for purposes of Paragraph 19 below, King Pharmaceuticals, Inc.
(“King”); through their authorized representatives. (Collectively, all of the above will be
referred to as “the Parties.”)

PREAMBLE

     As a preamble to this Agreement, the Parties agree to the following:

     A. Alpharma Inc. is a Delaware corporation with its principal place of business in New Jersey.
At all relevant times, Alpharma Inc., through its subsidiary, Alpharma Pharmaceuticals LLC,
developed, manufactured, distributed, marketed and sold pharmaceutical products in the United
States, including the morphine-based drug sold under the trade name of Kadian. Hereafter, Alpharma
Inc. and Alpharma Pharmaceuticals LLC, will be collectively referred to as “Alpharma.” In December
2008, King effectuated a short-form merger agreement between one of King’s wholly-owned
subsidiaries, Albert Acquisition Corp., and Alpharma. As a result of this merger agreement,
Alpharma became a wholly-owned subsidiary of King. At the time King acquired Alpharma, King also
entered into an asset purchase agreement with Actavis Elizabeth, LLC. to divest all assets
comprising Kadian.

     B. Relator Debra Parks is an individual resident of Florida. In September 2006, Relator Parks
filed a qui tam action against Alpharma Inc. and other defendants that is currently
pending and that is captioned: U.S. et al. ex rel. Debra Parks v. Alpharma Inc., et al.,
Civil

 

 

Action No. AMD 06-2411 (D. MD). This action is referred to below as the “Civil Action.” The
Relator and Alpharma agree that the complaint in the Civil Action alleges misconduct that continues
through, but does not extend past, December 29, 2008. This complaint has been twice amended.

     C. Alpharma has entered into or will be entering into separate settlement agreements,
described in Paragraph 1(b) below (hereinafter referred to as the “Medicaid State Settlement
Agreement”) with certain states and the District of Columbia in settlement of the Covered Conduct.
States with which Alpharma executes a Medicaid State Settlement Agreement in the form to which
Alpharma and the National Association of Medicaid Fraud Control Units (“NAMFCU”) Negotiating Team
have agreed, or in a form otherwise agreed to by Alpharma and an individual State, shall be defined
as “Medicaid Participating States.”

     D. The United States alleges that Alpharma caused to be submitted claims for payment for
Kadian to the Medicaid Program (“Medicaid”), Title XIX of the Social Security Act, 42 U.S.C. §§
1396-1396v. The United States further alleges that Alpharma caused claims for payment for Kadian
to be submitted to the TRICARE Program (“TRICARE”), 10 U.S.C. §§ 1071-1109; and the Federal
Employees Health Benefits Program (“FEHBP”), 5 U.S.C. §§ 8901-8914 (collectively, the “other
Federal Health Care Programs”). The United States additionally alleges that Alpharma caused
certain claims for payment for Kadian to be submitted to the Medicare Program (“Medicare”), Title
XVIII of the Social Security Act, 42 U.S.C. §§ 1395-1395hhh.

     E. The United States contends that it and the Medicaid Participating States have certain civil
claims, as specified in Paragraph 2 below, against Alpharma due to Alpharma having engaged in the
following conduct (hereinafter referred to as the “Covered Conduct”):

2

 

During the period of January 1, 2000 through December 29, 2008, (a) offering and paying
illegal remuneration to health care professionals in connection with advisory boards, speakers’
bureaus or training programs, educational or research grants, consulting forums or other
consultancies, preceptorships, or arrangements to make patient enrollment payments in connection
with educational or research grants, to induce health care professionals to promote and/or
prescribe Kadian, in violation of the Federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), and
(b) making and/or disseminating unsubstantiated and/or false representations or statements,
directly or indirectly, about the safety and efficacy of Kadian to promote or encourage prescribing
of Kadian for uses that were not reasonable and necessary. As a result of the foregoing conduct,
Alpharma knowingly caused false or fraudulent claims for Kadian to be submitted to Medicaid,
Medicare and the other Federal Health Care Programs.

     F. The United States also contends that it has certain administrative claims against Alpharma
as specified in Paragraphs 3 through 5, below, for engaging in the Covered Conduct.

     G. In the Civil Action, the Relator has also asserted claims against Alpharma for payment of
reasonable attorneys’ fees and costs, pursuant to 31 U.S.C. § 3730(d), and for alleged wrongful
termination, pursuant to 31 U.S.C. § 3730(h). In a separate action, Relator has also asserted
claims against Alpharma and King for wrongful discharge under Maryland law. These claims are not
resolved by this Agreement, as set forth in Paragraph 7 below.

     H. This Agreement is made in compromise of disputed claims. This Agreement is not an
admission of facts or liability by Alpharma. This Agreement is also not a concession by the United
States that its claims are not well-founded. Alpharma expressly denies allegations of the United
States and the Relator as set forth herein and in the Civil Action and denies that they have
engaged in any wrongful conduct in connection with the Covered Conduct. Neither this

3

 

Agreement, its execution, nor the performance of any obligation under it, including any
payment, nor the fact of the settlement, is intended to be, or shall be understood as, an admission
of liability or wrongdoing, or other expression reflecting upon the merits of the dispute, by
Alpharma.

     I. To avoid the delay, uncertainty, inconvenience, and expense of protracted litigation of
these claims, the Parties reach a full and final settlement as set forth in this Agreement.

TERMS AND CONDITIONS

     NOW, THEREFORE, in reliance on the representations contained herein and in consideration of
the mutual promises, covenants, and obligations in this Agreement, and for good and valuable
consideration, as set forth herein, the Parties agree as follows:

     1. Alpharma Inc. and Alpharma Pharmaceuticals LLC agree to pay to the United States and the
Medicaid Participating States, collectively, the sum of forty-two million five hundred thousand
dollars ($42,500,000.00), plus interest at the rate of 3.125% per annum on that amount from October
1, 2009 (collectively, the “Settlement Amount”). The Settlement Amount shall constitute a debt due
and owing to the United States and the Medicaid Participating States on the dates set forth in
Subparagraphs (a) and (b) of this Paragraph. This debt shall be discharged by payments to the
United States and the Medicaid Participating States, under the following terms and conditions:

     (a) Alpharma shall pay to the United States the sum of thirty-three million six hundred
twenty-four thousand and thirty-five dollars ($33,624,035.00) plus accrued interest on that amount
from October 1, 2009 and continuing until and including the day before payment is made under this
Agreement (“Federal Settlement Amount”), within ten days of the Effective

4

 

Date of this Agreement, as defined in Paragraph 29. The Federal Settlement Amount shall be
paid by electronic funds transfer pursuant to written instructions from the Department of Justice.

     (b) Alpharma shall pay to the Medicaid Participating States the sum of eight million eight
hundred seventy-five thousand nine hundred and sixty five dollars ($8,875,965.00) plus accrued
interest (“Medicaid State Settlement Amount”). The payment of the Medicaid State Settlement Amount
shall be made at such time and in such manner as shall be negotiated between Alpharma and the
NAMFCU Negotiating Team under the terms and conditions of the Medicaid State Settlement Agreements
into which Alpharma will enter with the Medicaid Participating States.

     (c) The United States agrees that, pursuant to 31 U.S.C. § 3730(d)(1), it shall pay to the
Relator, through her legal counsel, fifteen point eighty six (15.86) percent of the Federal
Settlement Amount or any portion thereof actually recovered under this Agreement. Payment to the
Relator is referred to herein as the “Relator’s share.” The United States agrees that after ninety
(90) days of receipt of payment of any portion of the Federal Settlement Amount, the United States
will pay to the Relator an amount equal to 15.86 percent of the payment; provided however that in
the event a bankruptcy proceeding involving Alpharma is commenced within ninety days of receipt of
payment, the United States will pay the Relator’s share as soon as feasible after receiving the
payment from King referenced in Paragraph 19 below. Payment of the Relator’s share under this
Agreement shall be made by electronic funds transfer to a trust account in the name of the Relator
in accordance with the written instruction of Relator’s counsel.

     2. Subject to the exceptions in Paragraph 10 below, in consideration of the obligations of
Alpharma set forth in this Agreement, conditioned upon the payment in full of the

5

 

Settlement Amount by Alpharma, and subject to Paragraph 18 below (concerning bankruptcy
proceedings commenced within 91 days of the Effective Date of this Agreement or any payment made
under this Agreement), the United States (on behalf of itself, its officers, agents, agencies, and
departments) agrees to release Alpharma, its predecessors, and their current and former divisions,
parents, affiliates, subsidiaries, successors, and assigns (the “Released Alpharma Entities”) and
their current and former directors, officers, and employees (the “Released Alpharma Individuals”)
(collectively, the Released Alpharma Entities and the Released Alpharma Individuals shall be
referred to as the “Released Alpharma Entities and Individuals”), from any civil or administrative
monetary claim that the United States has or may have for the Covered Conduct under the False
Claims Act, 31 U.S.C. §§ 3729-3733; the Civil Monetary Penalties Law, 42 U.S.C. § 1320a-7a; the
Program Fraud Civil Remedies Act, 31 U.S.C. §§ 3801-3812; any statutory provision for which the
Civil Division of the Department of Justice has actual and present authority to assert and
compromise pursuant to 28 C.F.R. Part 0, Subpart I, 0.45 (d) (1995) for the Covered Conduct, and
the common law claims of fraud, unjust enrichment and payment by mistake for the Covered Conduct.
[Material redacted pursuant to order of the United States District Court for the District of
Maryland, Civil No. RDB-06-2411 (March 16, 2010).]

     3. OIG-HHS expressly reserves all rights to institute, direct, or to maintain any
administrative action seeking exclusion against Alpharma and/or King, and/or their officers,
directors, and employees, from Medicare, Medicaid, and all other Federal health care programs (as
defined in 42 U.S.C. § 1320a-7b(f)) under 42 U.S.C. § 1320a-7(a) (mandatory exclusion), or 42
U.S.C. § 1320a-7(b) or 42 U.S.C. § 1320a-7a (permissive exclusion).

6

 

     4. TMA expressly reserves all rights to institute, direct, or to maintain any administrative
action seeking exclusion against Alpharma and/or King from the Tricare Program under 32 C.F.R.
Chapter 199.9, including both mandatory and permissive exclusions.

     5. OPM expressly reserves all rights to institute, direct, or to maintain any administrative
action seeking debarment against Alpharma and/or King from the FEHBP under 5 U.S.C. § 8902(b)
(mandatory debarment), or 5 U.S.C. § 8902 (c) and (d) (permissive debarment).

     6. Conditioned upon receipt of the Relator’s share set forth in Paragraph 1(c) above, the
Relator, for herself individually, and for her heirs, successors, agents, and assigns, fully and
finally releases, waives, and forever discharges the United States, its officers, agents, and
employees, from any claims arising from or relating to 31 U.S.C. § 3730 for any claims against
Alpharma arising from the Covered Conduct and/or for any other claims in the Civil Action; and from
any other claims for a share of the Settlement Amount, and in full settlement of any claims Relator
may have against the United States under this Agreement. Nothing in this Paragraph or any other
provision of this Agreement resolves, or in any manner affects, any claims the United States has or
may have against the Relator arising under Title 26, U.S. Code (Internal Revenue Code), or any
claims arising under this Agreement.

     7. The Relator also agrees that:

          (a) Conditioned upon the full and complete payment of the Settlement Amount by Alpharma to the
United States and the Medicaid Participating States, the Relator, for herself, and for her heirs,
successors, agents, and assigns, fully and finally releases, waives, and forever discharges the
Released Alpharma Entities and Individuals from any and all claims, liabilities, demands, damages,
actions or causes of action arising from the allegations in the Civil

7

 

Action for the period from
January 1, 2000 through December 29, 2008, whether known or
unknown, fixed or contingent, in law or in equity, that she has or may have, on behalf of
herself or any other person, entity, or thing, including the United States, or any state or local
government or sovereign, except as provided in paragraph 7 (c) below (“Relator’s Claims”);

          (b) The Relator has not assigned or transferred any of the Relator’s Claims to any person,
entity, or thing, and covenants and agrees not to assert or pursue any of the Relator’s Claims in
any way, including by offset or recoupment; and

          (c) Notwithstanding the above provisions of this Paragraph, the Relator does not release the
Released Alpharma Entities and Individuals from (i) Relator’s claims for reasonable attorneys’ fees
and cost in connection with the Civil Action, pursuant to 31 U.S.C. § 3730(d), and (ii) Relator’s
claims that are based on allegations that Alpharma wrongfully retaliated against the Relator in
violation of the anti-retaliation provisions of the FCA, 31 U.S.C. § 3730(h), and (iii) Relator’s
claims that are based on allegations that Alpharma wrongfully terminated relator’s employment which
are pending in the Circuit Court of Maryland for Baltimore City Circuit Court Case Number
24-C-09-004512 OT. As stated in Paragraph 20 of this Agreement, the claims described in this
sub-paragraph are not being released by any provision in this Agreement. The purpose of this
sub-paragraph is to exclude and exempt the claims described in this sub-paragraph from being
released in any manner. The Released Alpharma Entities and Individuals specifically agree that
they will not raise this release, or Relator’s signature on this release as grounds for dismissal
or judgment in favor the Released Alpharma Entities and Individuals on the claims described in this
sub-paragraph; and

          (d) No portion of the Relator’s share paid to Relator by the United States or the Medicaid
Participating States is intended to compensate, or does compensate, Relator for any

8

 

damages
compensable under 31 U.S.C. § 3730(h) or damages Relator seeks to recover through
her claims asserted in the Circuit Court of Maryland for Baltimore City, Case Number
24-C-09004512 OT.

     8. Alpharma fully and finally releases the United States, and its agencies, employees,
servants, and agents from any claims (including attorneys’ fees, costs and expenses of every kind
and however denominated) which Alpharma has asserted, could have asserted, or may assert in the
future against the United States, its agencies, employees, servants, and agents, related to the
Covered Conduct or arising from the United States’ investigation and prosecution of the Civil
Action.

     9. In consideration of the obligations of the Relator set forth in this Agreement, Alpharma,
on behalf of itself and the other Alpharma Released Entities and Individuals, fully and finally
releases, waives, and forever discharges the Relator and her heirs, successors, assigns, agents,
and attorneys from any claims or allegations that Alpharma has asserted or could have asserted,
arising from the allegations in the Civil Action for the period from January 1, 2000 through
December 29, 2008. Notwithstanding the foregoing, this Paragraph does not release or foreclose the
assertion of any defenses or counterclaims available to the Alpharma Released Entities and
Individuals with respect to the claims reserved by Relator pursuant to Paragraph 7(c) above.

     10. Notwithstanding any term of this Agreement, specifically reserved and excluded from the
scope and terms of this Agreement as to any entity or person (including Alpharma and the Relator)
are the following claims of the United States:

          (a) Any civil, criminal, or administrative liability arising under Title 26, U.S. Code
(commonly referred to as the Internal Revenue Code);

9

 

          (b) Any criminal liability;

          (c) Except as explicitly stated in this Agreement, any administrative liability, including
permissive or mandatory exclusion from the Federal health care programs;

          (d) Any liability to the United States (or its agencies) for any conduct other than the
Covered Conduct;

          (e) Any liability based upon such obligations as are created by this Agreement;

          (f) Any liability for express or implied warranty claims or other claims for defective or
deficient products or services, including quality of goods and services;

          (g) Any liability for personal injury or property damage, or for other similar consequential
damages, arising from the Covered Conduct;

          (h) Any liability for failure to deliver goods or services due; or

          (i) Any civil or administrative liability of individuals (including current or former
directors, officers, employees, or agents of Alpharma) who receive written notification that they
are the target of a criminal investigation (as defined in the United States Attorneys’ Manual), are
indicted, charged, or convicted, or who enter into a criminal plea agreement arising from the
Covered Conduct.

     11. The Relator and her heirs, successors, attorneys, agents, and assigns agree not to object
to this Agreement and agree and confirm that this Agreement is fair, adequate, and reasonable under
all the circumstances, pursuant to 31 U.S.C. § 3730(c)(2)(B), and expressly waive the opportunity
for a hearing on any objection to this Agreement pursuant to 31 U.S.C. § 3730(c)(2)(B).

10

 

     12. Alpharma waives and shall not assert any defenses it may have to any criminal prosecution
or administrative action relating to the Covered Conduct that may be based in whole
or in part on a contention that, under the Double Jeopardy Clause in the Fifth Amendment of
the Constitution, or under the Excessive Fines Clause in the Eighth Amendment of the Constitution,
this Agreement bars a remedy sought in such criminal prosecution or administrative action. Nothing
in this Paragraph or any other provision of this Agreement constitutes an agreement by the United
States concerning the characterization of the Settlement Amount for purposes of the Internal
Revenue Laws, Title 26 of the United States Code.

     13. The Settlement Amount shall not be decreased as a result of the denial of claims for
payment now being withheld from payment by any Medicare carrier or intermediary, or any state
payer, related to the Covered Conduct; and Alpharma agrees not to resubmit to any Medicare carrier
or intermediary, or any state payer, any previously denied claims related to the Covered Conduct,
and agrees not to appeal any such denials of claims.

     14. Alpharma agrees to the following:

          (a) Unallowable Costs Defined: That all costs (as defmed in the Federal Acquisition
Regulation, 48 C.F.R. § 31.205-47 and in Titles XVIII and XIX of the Social Security Act, 42 U.S.C.
§§ 1395-1395hhh and 1396-1396v, and the regulations and official program directives promulgated
thereunder) incurred by or on behalf of the Released Alpharma Entities and Individuals in
connection with any of the following shall be “Unallowable Costs” on government contracts and under
the Medicare Program, Medicaid Program, TRICARE Program, and FEHBP:

               (1) the matters covered by this Agreement;

11

 

               (2) the United States’ audit, and any United States’ investigation of the matters covered by
this Agreement;

               (3) the Released Alpharma Entities investigation, defense, and any corrective actions
undertaken in response to the United States’ audit, and civil and criminal investigation, in
connection with the matters covered by this Agreement (including attorneys’ fees);

               (4) the negotiation and performance of this Agreement, and the Medicaid State Settlement
Agreements;

               (5) the payments that Alpharma makes to the United States or any State pursuant to this
Agreement, or the Medicaid State Settlement Agreements and any payment that Alpharma may make to
the Relator, including any costs and attorneys’ fees.

          (b) Future Treatment of Unallowable Costs: These Unallowable Costs shall be
separately determined and accounted for by Alpharma, and Alpharma shall not charge such Unallowable
Costs directly or indirectly to any contracts with the United States or any State Medicaid program,
or seek payment for such Unallowable Costs through any cost report, cost statement, information
statement or payment request submitted by any of the Released Alpharma Entities to the Medicare,
Medicaid, TRICARE, or FEHBP Programs.

          (c) Treatment of Unallowable Costs Previously Submitted for Payment: Alpharma further
agrees that, within 90 days of the Effective Date of this Agreement, it shall identify to
applicable Medicare and TRICARE fiscal intermediaries, carriers, and/or contractors, and Medicaid
and FEHBP fiscal agents, any Unallowable Costs (as defined in this Paragraph) included in payments
previously sought from the United States, or any State Medicaid program, including, but not limited
to, payments sought in any cost reports, cost statements, information

12

 

reports, or payment requests
already submitted by any of the Released Alpharma Entities, and shall request, and agree, that such
cost reports, cost statements, information reports, or payment
requests, even if already settled, be adjusted to account for the effect of the inclusion of
the Unallowable Costs. Alpharma agrees that the United States, at a minimum, shall be entitled to
recoup from Alpharma any overpayment, plus applicable interest and penalties, as a result of the
inclusion of such Unallowable Costs on previously submitted cost reports, information reports, cost
statements, or requests for payment.

     Any payments due after the adjustments have been made shall be paid to the United States
pursuant to the direction of the Department of Justice and/or the affected agencies. The United
States reserves its rights to disagree with any calculations submitted by the Released Alpharma
Entities on the effect of inclusion of Unallowable Costs (as defined in this Paragraph) on the cost
reports, cost statement, or information reports of the Released Alpharma Entities.

          (d) Nothing in this Agreement shall constitute a waiver of the rights of the United States to
audit, examine, or re-examine the books and records of the Released Alpharma Entities to determine
that no Unallowable Costs have been claimed in accordance with the provisions of this Paragraph.

     15. This Agreement is intended to be for the benefit of the Parties only. The Parties do not
release any claims against any other individual, employee, or entity, except to the extent provided
for specifically herein.

     16. Alpharma agrees that it waives and shall not seek payment for any of the health care
billings covered by this Agreement from any health care beneficiaries or their parents, sponsors,
legally responsible individuals, or third party payors based upon the claims defined as Covered
Conduct.

13

 

     17. Alpharma expressly warrants that it has reviewed its financial situation and that it is
currently solvent within the meaning of 11 U.S.C. §§ 547(b)(3) and 548 (a)(1)(B)(ii)(I), and
will remain solvent following payment of the Settlement Amount. Further, the Parties warrant
that, in evaluating whether to execute this Agreement, they (a) have intended that the mutual
promises, covenants, and obligations set forth herein constitute a contemporaneous exchange for new
value given to Alpharma, within the meaning of 11 U.S.C. § 547(c)(1); and (b) conclude that these
mutual promises, covenants, and obligations do, in fact, constitute such a contemporaneous
exchange. Further, the Parties warrant that the mutual promises, covenants, and obligations set
forth herein are intended to, and do, in fact, represent a reasonably equivalent exchange of value
which is not intended to hinder, delay, or defraud any entity to which Alpharma was or became
indebted to on or after the date of this transfer, within the meaning of 11 U.S.C. § 548(a)(1).

     18. In the event that Alpharma Inc. or Alpharma Pharmaceuticals LLC. commences, or a third
party commences, within 91 days of the Effective Date of this Agreement, or of any payment made
hereunder, any case, proceeding, or other action under any law relating to bankruptcy, insolvency,
reorganization, or relief of debtors, (a) seeking to have any order for relief of Alpharma Inc.’s
or Alpharma Pharmaceutical LLC’s debts, or seeking to adjudicate either of these entities as
bankrupt or insolvent; or (b) seeking appointment of a receiver, trustee, custodian, or other
similar official for either of these entities for all or any substantial part of either of these
entities’ assets, Alpharma agrees as follows:

          (a) Alpharma’s obligations under this Agreement may not be avoided pursuant to 11 U.S.C. §§
547 or 548, and Alpharma shall not argue or otherwise take the position in any such case,
proceeding, or action that: (i) Alpharma’s obligations under this Agreement 

14

 

may be avoided under
11 U.S.C. §§ 547 or 548; (ii) Alpharma was insolvent at the time this Agreement was entered into,
or became insolvent as a result of any payment made to the United
States hereunder; or (iii) the mutual promises, covenants, and obligations set forth in this
Agreement do not constitute a contemporaneous exchange for new value given to Alpharma.

          (b) If Alpharma’s obligations under this Agreement are avoided for any reason, including, but
not limited to, through the exercise of a trustee’s avoidance powers under the Bankruptcy Code, and
if the obligations of Alpharma are not discharged by King pursuant to Paragraph 19 within 30 days
after demand by the United States upon King, the United States, at its sole option, may rescind the
releases in this Agreement, and bring any civil and/or administrative claim, action, or proceeding
against Alpharma for the claims that would otherwise be covered by the releases provided in
Paragraph 2 above. Alpharma agrees that (i) any such claim, action, or proceeding brought by the
United States (including any proceeding to exclude any of the Released Alpharma
Entities/Individuals from participation in Medicare, Medicaid, or other Federal health care
programs) are not subject to an “automatic stay” pursuant to 11 U.S.C. § 362(a) as a result of the
action, case, or proceeding described in the first clause of this Paragraph, and that Alpharma
shall not argue or otherwise contend that the United States’ claim, action, or proceeding is
subject to an automatic stay; (ii) Alpharma shall not plead, argue, or otherwise raise any defenses
under the theories of statute of limitations, laches, estoppel, or similar theories, to any such
civil or administrative claim, action, or proceeding that is brought by the United States within
one-hundred-twenty (120) calendar days of written notification to Alpharma that the releases have
been rescinded pursuant to this Paragraph, except to the extent such defenses were available on
September 13, 2006, the date the Civil Action case was originally filed; and (iii) the United
States has a valid claim against Alpharma for the Covered

15

 

Conduct in the amount of treble damages
plus penalties, as provided for under the False Claims
Act, 31 U.S.C. §§ 3729-3733, and the United States may pursue its claims in any case, action,
or proceeding referenced in the first clause of this subparagraph.

          (c) Alpharma acknowledges that its agreements in this Paragraph are provided in exchange for
valuable consideration provided in this Agreement.

     19. In order to induce the United States to enter into this Settlement Agreement with
Alpharma, and in consideration for the benefits that King, in its capacity as sole stockholder of
Alpharma, will realize from this Settlement Agreement, King hereby absolutely, unconditionally and
irrevocably guarantees to the United States the payment in full of the Federal Settlement Amount
when due. King hereby waives any defense to its obligations under this Paragraph 19, other than
the complete and indefeasible payment by Alpharma or King of the Federal Settlement Amount, or a
rescission by the United States pursuant to Paragraph 18. In the event that, within the 90-day
period following payment of the Settlement Amount during which a payment by Alpharma can
potentially be set aside under the United States bankruptcy laws as a preference, Alpharma becomes
subject to a bankruptcy proceeding, and counsel for the United States informs counsel for King, in
writing, that the United States has determined that some or all of the funds that it received from
Alpharma may be set aside as a preference, then the United States may declare Alpharma in breach of
its obligations hereunder and return the funds received from Alpharma as the Federal Settlement
Amount (without discharging Alpharma for its liability for such payment), and within ten business
days after the date that such funds are returned, King, in its capacity as guarantor of Alpharma’s
obligation shall pay to the United States the sum of thirty-three million six hundred twenty-four
thousand and thirty-five dollars ($33,624,035.00)

16

 

plus interest at the rate of 3.125 percent per
annum on that amount from October 1, 2009 to the date that King makes its payment as guarantor.

     20. Within 30 days of the Effective Date of this Agreement, the United States shall: intervene
in the Civil Action as to the Covered Conduct, consent to the voluntary dismissal as to defendants
Alpharma Inc., Alpharma Branded Products Division, Inc., Faulding Laboratories, and Purepac
Pharmaceutical Company as to all allegations against these defendants that are set forth in the
Civil Action, except those claims referenced in subparagraph (c) of this Paragraph, and file a
stipulation of dismissal in the Civil Action as follows:

          (a) the stipulation of dismissal shall be with prejudice as to both the United States’ and
Relator’s claims against Alpharma as to the Covered Conduct, pursuant to and consistent with the
terms and conditions of this Agreement, and conditioned upon Alpharma’s payment in full of the
Settlement Amount;

          (b) the stipulation of dismissal shall be without prejudice as to the United States and with
prejudice as to the Relator as to all other claims in the Civil Action against Alpharma Inc.,
Alpharma Branded Products Division, Inc., Faulding Laboratories, and Purepac Pharmaceutical
Company;

          (c) provided, however, that the following claims in the Civil Action against Alpharma shall
not be dismissed unless they are settled, adjudicated, or otherwise resolved: (1) the Relator’s
claims for reasonable attorneys’ fees, expenses, and costs pursuant to 31 U.S.C. § 3730(d); and (2)
the Relator’s claims under 31 U.S.C. § 3730(h).

     21. Except as expressly provided for to the contrary in this Agreement, each Party shall bear
its own legal and other costs incurred in connection with this matter, including the

17

 

preparation
and performance of this Agreement, except that the Relator reserves her rights against Alpharma to
seek attorney’s fees, costs and expenses under § 3730(d).

     22. The Parties each represent that this Agreement is freely and voluntarily entered into
without any degree of duress or compulsion whatsoever.

     23. This Agreement is governed by the laws of the United States. The Parties agree that the
exclusive jurisdiction and venue for any dispute arising between or among the Parties under this
Agreement, including any dispute regarding payment of the Relator’s attorney’s fees, expenses and
costs, or the Relator’s claims under § 3730(h), will be in the United States District Court for the
District of Maryland.

     24. For purposes of construction, this Agreement shall be deemed to have been drafted by all
Parties to this Agreement and shall not, therefore, be construed against any party for that reason
in any dispute.

     25. The individuals signing this Agreement on behalf of Alpharma and King warrant that they
are authorized by Alpharma and King to execute this Agreement. The United States’ signatories
represent that they are signing this Agreement in their official capacities and that they are
authorized to execute this Agreement. The individuals signing this Agreement on behalf of the
Relator represent and warrant that they are authorized by the Relator to execute this Agreement.

     26. This Agreement may be executed in counterparts, each of which constitutes an original and
all of which constitute one and the same Agreement.

     27. This Agreement is binding on the successors, transferees, heirs, and assigns of Alpharma,
King and Relator.

18

 

     28. All Parties consent to the disclosure of this Agreement, and information about this
Agreement, to the public after it has been finally executed.

     29. This Agreement is effective on the date of signature of the last signatory to the
Agreement (“Effective Date”). Facsimiles of signatures shall constitute acceptable, binding
signatures for purposes of this Agreement.

     30. This Agreement may not be amended except by the written consent of the affected Parties.
This Agreement constitutes the complete agreement between the Parties with respect to the issues
covered by the Agreement.

          IN WITNESS WHEREOF, the parties hereto affix their signatures:

19

 

FOR THE UNITED STATES OF AMERICA

	 	 	 	 	 	 	 	 	 

	DATED:

	 	 	 	BY:
	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	JAMIE BENNETT	 	 
	 	 	 	 	 	 	THOMAS CORCORAN	 	 
	 	 	 	 	 	 	Assistant United States Attorneys	 	 
	 	 	 	 	 	 	District of Maryland	 	 
	 
	 	 	 	 	 	 	 	 
	DATED:

	 	 	 	BY:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	DANIEL SPIRO	 	 
	 	 	 	 	 	 	Senior Trial Counsel	 	 
	 	 	 	 	 	 	Commercial Litigation Branch, Civil
Division United States Department of
Justice	 	 
	 
	 	 	 	 	 	 	 	 
	DATED:

	 	 	 	BY:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	LAUREL C. GILLESPIE	 	 
	 	 	 	 	 	 	Deputy General Counsel	 	 
	 	 	 	 	 	 	Tricare Management Activity	 	 
	 	 	 	 	 	 	United States Department of Defense	 	 
	 
	 	 	 	 	 	 	 	 
	DATED:

	 	 	 	BY:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	GREGORY E. DEMSKE	 	 
	 	 	 	 	 	 	Assistant Inspector General for Legal	 	 
	 	 	 	 	 	 	Affairs Office of Inspector General
United States Department of Health and
Human Resources	 	 
	 
	 	 	 	 	 	 	 	 
	DATED:

	 	 	 	BY:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	SHIRLEY R. PATTERSON	 	 
	 	 	 	 	 	 	Assistant Director for Insurance Services

Programs	 	 
	 	 	 	 	 	 	Center for Retirement & Insurance
Services United States Office of
Personnel Management	 	 

20

 

FOR ALPHARMA AND KING

	 	 	 	 	 	 	 	 	 

	DATED:

	 	 	 	BY:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	WILL PHILLIPS	 	 
	 	 	 	 	 	 	Assistant General Counsel and Assistant
Secretary	 	 
	 	 	 	 	 	 	Alpharma Pharmaceuticals LLC	 	 
	 
	 	 	 	 	 	 	 	 
	DATED:

	 	 	 	BY:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	RIC BRUCE	 	 
	 	 	 	 	 	 	President	 	 
	 	 	 	 	 	 	Alpharma Inc.	 	 
	 
	 	 	 	 	 	 	 	 
	DATED:

	 	 	 	BY:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	JAMES ELROD	 	 
	 	 	 	 	 	 	Chief Legal Officer	 	 
	 	 	 	 	 	 	King Pharmaceuticals, Inc.	 	 
	 
	 	 	 	 	 	 	 	 
	DATED:

	 	 	 	BY:	 	 	 	 
	 

	 	 
	 	 	 	 	 	 
	 	 	 	 	 	 	GEOFFREY HOBART	 	 
	 	 	 	 	 	 	MATTHEW O’CONNOR	 	 
	 	 	 	 	 	 	Covington & Burling LLP	 	 
	 	 	 	 	 	 	Counsel for Alpharma Inc., Alpharma	 	 
	 	 	 	 	 	 	Pharmaceuticals LLC, and King	 	 
	 	 	 	 	 	 	Pharmaceuticals, Inc.	 	 

21

 

FOR THE RELATOR

	 	 	 	 	 	 	 	 	 

	DATED:

	 	 	 	BY:	 	 	 	 
	 

	 	 

	 	 	 	 

	 	 
	 	 	 	 	 	 	DEBRA PARKS	 	 
	 
	 	 	 	 	 	 	 	 
	DATED:

	 	 	 	BY:	 	 	 	 
	 

	 	 

	 	 	 	 

	 	 
	 	 	 	 	 	 	MARY LOUISE COHEN, Esq.	 	 
	 	 	 	 	 	 	TIMOTHY McCORMACK	 	 
	 	 	 	 	 	 	Phillips & Cohen LLP.	 	 
	 	 	 	 	 	 	Counsel for Relator Debra Parks	 	 

22

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}]]